StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
TD Cowen on Royalty Pharma (RPRX): BIIB Ph2 results 'de-risks upside potential for royalty'
March 31, 2026 8:14 AM
TD Cowen analyst Steve Scala reiterated a Buy rating and $50.00 price target on Royalty Pharma (NASDAQ: RPRX)The analyst commented ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
